LKFT.AS
Strong BuyFull HouseAI neutralLakefront Biotherapeutics NV · Healthcare · Belgium · $2.1B cap · $2.8M/day traded
EUR 28.44 -1.7% · close 2 Nov · scored 3 Nov
Full House: Strong business, sensible price, and the market agrees.
Read our full research report on LKFT.AS (May 2026), freeAs of 3 Nov 2026, MoatMap's StockRank for Lakefront Biotherapeutics NV (LKFT.AS) is 98/100, ranked against 24,000+ stocks in 35 markets (Quality 73, Value 85, Momentum 57, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
Lakefront Biotherapeutics is a biotechnology company that has partnered with Gilead, including on the acquisition of Ouro Medicines to expand an inflammation pipeline. Its value depends on clinical and partnering outcomes that are hard to judge from available information, and third-party valuation models claiming very large upside are not a reliable guide for a pipeline business. The case is binary rather than a compounding one.
ABOUT LAKEFRONT BIOTHERAPEUTICS NV
Read
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 241.2M | 239.7M | 275.6M | 1.1B | 66.4% | 988.4M | 117.2M | 84.6M | -72.4% |
| EPS (EUR) | -3.32 | 3.21 | 1.12 | 4.87 | 23.2% | 9.00 | — | — | — |
| Shares | 65.8M | 65.9M | 65.9M | 65.9M | +0.1% | 65.9M | — | — | — |
| Debt | 21.9M | 9.6M | 11.7M | 6.9M | -31.9% | 6.3M | — | — | — |
| Equity | 2.5B | 2.8B | 2.9B | 3.2B | 8.6% | — | — | — | — |
| Op CF | -500.5M | -406.0M | -320.0M | -257.5M | — | -226.4M | — | — | — |
| Inv CF | -1.2B | 71.2M | 220.6M | 288.8M | — | — | — | — | — |
| Fin CF | -1.5M | -5.0M | -4.9M | -3.3M | — | — | — | — | — |
27% above its 52-week low and back above a rising 50-day average since 2 Oct 2026.
Calmer than 77% of stocks we rank over the past year (volatility 28% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LKFT.AS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LKFT.AS | Lakefront Biotherapeutics NV(you) | $2.1B | 98 | Strong Buy |
| UCB.BR | UCB SA | $58.3B | 87 | Strong Buy |
| TUB.BR | Financière de Tubize SA | $11.0B | 47 | Hold |
| AGMB | AgomAb Therapeutics NV | $446M | 14 | Strong Sell |
| FAGR.BR | Fagron NV | $1.9B | 78 | Buy |
| HYL.BR | Hyloris Pharmaceuticals SA | $124M | 13 | Strong Sell |
| IBAB.BR | Ion Beam Applications SA | $520M | 71 | Buy |
| SEQUA.BR | Sequana Medical NV | $54M | 16 | Strong Sell |
| NYXH | Nyxoah SA | $85M | 6 | Strong Sell |
| MDXH | MDxHealth SA | $58M | 14 | Strong Sell |
Peer medians: ROE -6.1% · P/E 22.2x · Gross margin 61.5%
Company Deep Dive
Read the full report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.